Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCl-HIBO
Discontinued Product
Cl-HIBO (Cat. No. 1673) has been withdrawn from sale for commercial reasons.
Description: GluA1 and GluA2 selective AMPA agonist
Alternative Names: 4-Chlorohomoibotenic acid
Chemical Name: (RS)-2-Amino-3-(4-chloro-3-hydroxy-5-isoxazolyl)propionic acid
Purity: ≥99% (HPLC)
Biological Activity for Cl-HIBO
Cl-HIBO is a subtype-selective and strongly desensitizing AMPA receptor agonist; selective for GluA1 and GluA2 subunit-containing receptors (EC50 values are 4.7, 1.7, 2700 and 1300 μM for rat recombinant homomeric GluA1-4 receptors respectively).
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
Technical Data for Cl-HIBO
| M. Wt | 206.59 |
| Formula | C6H7ClN2O4 |
| Storage | Store at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 909400-43-7 |
| PubChem ID | 4694356 |
| InChI Key | FDSXCQTXUSQQFH-UHFFFAOYSA-N |
| Smiles | ClC1=C(CC(C(O)=O)N)ON=C1O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for Cl-HIBO
References for Cl-HIBO
References are publications that support the biological activity of the product.
Bjerrum et al (2003) Design, synthesis, and pharmacology of a highly subtype-selective GluR1/2 agonist, (RS-2-amino-3-(4-chloro-3-hydroxy-5-isoxazolyl)propionic acid (Cl-HIBO). J.Med.Chem. 46 2246 PMID: 12747796
Kristensen et al (2002) Pharmacological characterization of 4-chlorohomoibotenic acid: a GluR1 and -2 subtype-selective agonist. Soc.Neurosci.Abstr. 540.7
View Related Products by Target
View Related Products by Product Action
Keywords: Cl-HIBO, Cl-HIBO supplier, Subtype-selective, AMPA, agonists, GluR1, GluR2, Glutamate, Receptors, iGluR, Ionotropic, Chloro-homoibotenic, acid, GluA1, GluA2, 4-Chlorohomoibotenic, 1673, Tocris Bioscience
Citations for Cl-HIBO
Citations are publications that use Tocris products.
Currently there are no citations for Cl-HIBO.
Reviews for Cl-HIBO
There are currently no reviews for this product. Be the first to review Cl-HIBO and earn rewards!
Have you used Cl-HIBO?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Ion Channel Product Listing
A collection of around 500 products for ion channel research, the listing includes research tools for the study of:
- Ligand-gated ion channels
- Voltage-gated ion channels
- Other Ion Channels
Pain Research Product Guide
A collection of over 280 products for pain research, the guide includes research tools for the study of:
- Nociception
- Ion Channels
- G-Protein-Coupled Receptors
- Intracellular Signaling
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's Poster
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy Poster
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Pain Poster
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's PosterUpdated
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia Poster
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.